Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.94 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 19.5× Tango Therapeutics Inc.'s market cap, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 92 Days on average.
| TNGX | VTIP | |
|---|---|---|
Market Cap | $3.75B | $73.20B |
Volume | 9,619,106 | 3,980,495 |
Sector | Health | — |
52-Week High | $32.90 | $50.46 |
52-Week Low | $7.50 | $48.38 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.46, down slightly by 0.06% on the day. The technical picture is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes, with institutional buying noted. Key support is at $48, resistance at $49.
The outlook for VTIP is cautious; it offers inflation protection but faces headwinds from persistent high rates. Risks include interest rate sensitivity and inflation volatility. Analyst sentiment is mixed, with some seeing value in short-duration TIPS, but the bearish technical trend suggests near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
